Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00686998 · ClinicalTrials.gov registry record · Phase 2
Phase IIA Study in Patients With Schizophrenia
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 106
- Enrollment target
NCT00686998 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 106 participants.
The verdict
NCT00686998, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 106 participants
- Enrollment target
Study Summary
This study is designed to assess the effects of AZD 2624 in patients with schizophrenia
Interventions
- DRUG Placebo
- DRUG Olanzapine
- DRUG AZD2624
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 106 participants |
| Start Date | 2008-05 |
| Est. Completion | 2009-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00686998
The ClinicalTrials.gov registry entry for NCT00686998 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 106 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00686998 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00686998 about?
NCT00686998 is a clinical study titled "Phase IIA Study in Patients With Schizophrenia". This study is designed to assess the effects of AZD 2624 in patients with schizophrenia
What is the current status of trial NCT00686998?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 106 participants. The study started on 2008-05. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00686998?
The interventions under investigation include: Placebo (DRUG), Olanzapine (DRUG), AZD2624 (DRUG).
Who is sponsoring clinical trial NCT00686998?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.